Protalix BioTherapeutics, Inc. (PLX)

$1.085

-0.01 (-0.46%)
Rating:
Recommendation:
Buy
Symbol PLX
Price $1.085
Beta 2.008
Volume Avg. 0.74M
Market Cap 51.064M
Shares () -
52 Week Range 0.7-2.0
1y Target Est -
DCF Unlevered PLX DCF ->
DCF Levered PLX LDCF ->
ROE -299.07% Strong Sell
ROA -25.92% Sell
Operating Margin -
Debt / Equity -1013.59% Strong Sell
P/E -
P/B -6.64 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PLX news


Mr. Dror Bashan
Healthcare
Biotechnology
American Stock Exchange

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.